HRTX

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapies to address unmet medical needs in acute care and oncology settings. Headquartered in San Diego, California, the company specializes in novel pain management and cancer care solutions. Heron's flagship product, ZYNRELEF, is an extended-release dual-acting local anesthetic that provides up to 72 hours of pain control following surgery, targeting the estimated 80 million surgical procedures performed annually in the United States. The company also markets CINVANTI and SUSTOL, both approved therapies for chemotherapy-induced nausea and vomiting (CINV). Heron operates through partnerships with healthcare facilities, ambulatory surgery centers, and oncology clinics across the United States. The company employs approximately 240 people and maintains its primary operations in California. In recent years, Heron has focused on expanding ZYNRELEF's commercial footprint in the post-surgical pain management market, pursuing additional regulatory approvals and label expansions. The company's business model centers on addressing acute care settings where effective, non-opioid pain management alternatives are increasingly sought by healthcare providers. Heron continues to invest in clinical development programs and commercial infrastructure to support its product portfolio while navigating the competitive pharmaceutical landscape focused on pain management innovation.